Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ascorbic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | MANBA | O00462 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.36 |
| ▸ | TST | Q16762 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL29384608 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL30215669 | 0.98 | LMNA (0.64) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL32679747 | 0.98 | LMNA (0.64) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL30356570 | 0.98 | LMNA (0.68) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL31150443 | 0.98 | LMNA (0.68) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21330886 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21768341 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21815619 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL21645349 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20839746 | 0.96 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2024-12-05 | — | — | US | disclosed |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | IC-MedTech Corp. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | IC-MedTech Corp. | 2024-05-23 | — | — | US | disclosed |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357383-A1 | Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C | SPHINGOTEC GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230149516-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM THERAGNOSTICS GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| EP-4110375-A1 | ANTI-ADM-ANTIBODIES BINDING TO THE FREE N-TERMINUS FOR ACCELERATED TRANSITION OF ADM-GLY TO BIO-ADM IN PATIENTS WITH ADM-GLY/ BIO-ADM RATIO ABOVE A THRESHOLD AND COMBINATION WITH VITAMIN C | sphingotec GmbH (DE) | 2023-01-04 | — | — | EP | disclosed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | disclosed |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | disclosed |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | disclosed |
| CN-115279399-A | anti-ADM antibodies binding to the free N-terminus and combinations thereof with vitamin C for accelerating the conversion of ADM-Gly to bio-ADM in patients with ADM-Gly/bio-ADM ratio above a threshold value | 思芬构技术有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-115243709-A | Use of peptidylglycine alpha-amidating monooxygenase (PAM) for therapeutic purposes | PAM治疗诊断有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | LMNA 1503/4885MAPT 2048/4885L3MBTL1 1103/4885 |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | NDUFB7, NDUFA12, NDUFB11 | LMNA 2837/4885MAPT 2119/4885L3MBTL1 3313/4885 |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | LMNA 1503/4885MAPT 2048/4885L3MBTL1 1103/4885 |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | NQO1, ADH7, TALDO1 | LMNA 1758/4885MAPT 1710/4885L3MBTL1 1049/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | LMNA 1503/4885MAPT 2048/4885L3MBTL1 1103/4885 |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | NQO1, SDHB, SDHA | LMNA 2639/4885MAPT 3180/4885L3MBTL1 3584/4885 |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | LMNA 1758/4885MAPT 1710/4885L3MBTL1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.